Annabel Samimy
Stock Analyst at Stifel
(4.46)
# 316
Out of 5,120 analysts
56
Total ratings
49.06%
Success rate
35.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Buy | $20 → $17 | $4.89 | +248.00% | 2 | Jan 13, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $15 → $18 | $10.96 | +64.23% | 1 | Dec 19, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | $50 → $55 | $48.74 | +12.86% | 8 | Dec 19, 2025 | |
| RGNX REGENXBIO | Maintains: Buy | $40 → $45 | $10.78 | +317.44% | 3 | Dec 19, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $35 → $40 | $29.03 | +37.79% | 2 | Dec 19, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $45 → $52 | $30.86 | +68.50% | 2 | Dec 19, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $45 → $50 | $39.07 | +27.98% | 2 | Dec 19, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $55 → $48 | $22.83 | +110.25% | 4 | Dec 19, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $220 → $230 | $197.93 | +16.20% | 2 | Dec 10, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $90 | $89.84 | +0.18% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $145 | $79.90 | +81.48% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.55 | +224.32% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $5.91 | +187.65% | 4 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $8.21 | +119.24% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $13.77 | +74.29% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $29.92 | +167.38% | 6 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $230 | $167.29 | +37.49% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.20 | +1,900.00% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $2.29 | +32,722.76% | 3 | Apr 16, 2020 |
Evolus
Jan 13, 2026
Maintains: Buy
Price Target: $20 → $17
Current: $4.89
Upside: +248.00%
Trevi Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $15 → $18
Current: $10.96
Upside: +64.23%
Supernus Pharmaceuticals
Dec 19, 2025
Maintains: Hold
Price Target: $50 → $55
Current: $48.74
Upside: +12.86%
REGENXBIO
Dec 19, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $10.78
Upside: +317.44%
Oculis Holding AG
Dec 19, 2025
Maintains: Buy
Price Target: $35 → $40
Current: $29.03
Upside: +37.79%
Mineralys Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $52
Current: $30.86
Upside: +68.50%
MBX Biosciences
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $39.07
Upside: +27.98%
Apellis Pharmaceuticals
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $22.83
Upside: +110.25%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $197.93
Upside: +16.20%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $50 → $90
Current: $89.84
Upside: +0.18%
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $79.90
Upside: +81.48%
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $5.55
Upside: +224.32%
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $5.91
Upside: +187.65%
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $8.21
Upside: +119.24%
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $13.77
Upside: +74.29%
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $29.92
Upside: +167.38%
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $167.29
Upside: +37.49%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.20
Upside: +1,900.00%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $2.29
Upside: +32,722.76%